Related Experiment Video
Updated: Mar 25, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke1, Camilla Engblom2, Steffen Rickelt3
1Center for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA 02114, USA.
Abstract:
Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung adenocarcinoma mouse models, including genetic models, we show that autochthonous tumors that lacked T cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and lacking Trp53) were used. The antitumor response was triggered by direct drug actions on tumor cells, relied on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended on CD8(+) T cell antitumor immunity. Furthermore, instigating tumor infiltration by T cells sensitized tumors to checkpoint inhibition and controlled cancer durably. These findings indicate that the proportion of cancers responding to checkpoint therapy can be feasibly and substantially expanded by combining checkpoint blockade with immunogenic drugs.
Insights
Checkpoint blockade immunotherapy is limited, but combining it with specific immunogenic drugs can sensitize non-infiltrated tumors to T cell immunity, expanding cancer treatment options.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Checkpoint blockade immunotherapies show promise but benefit a limited patient subset with pre-infiltrated tumors.
- Many tumors resist current treatments due to lack of T cell infiltration.
Purpose of the Study:
- To investigate methods for sensitizing non-T cell-infiltrated tumors to host antitumor immunity.
- To explore combination strategies to expand checkpoint blockade therapy efficacy.
Main Methods:
- Utilized lung adenocarcinoma mouse models, including genetic models.
- Administered selected immunogenic drugs (oxaliplatin and cyclophosphamide) to tumors lacking T cell infiltration.
- Assessed antitumor response, innate immune sensing via toll-like receptor 4, and CD8(+) T cell involvement.
Main Results:
- Autochthonous tumors lacking T cell infiltration were sensitized to antitumor T cell immunity by specific immunogenic drugs.
- The antitumor response was initiated by direct drug effects on tumor cells and innate immune sensing.
- Inducing T cell infiltration sensitized tumors to checkpoint inhibition, leading to durable cancer control.
Conclusions:
- Combining checkpoint blockade with immunogenic drugs can feasibly and substantially expand the proportion of cancers responding to immunotherapy.
- This strategy holds potential for overcoming resistance in non-infiltrated tumors and improving durable cancer control.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers